Inside Eli Lilly’s $6 Billion Bet to Rebuild Drug Manufacturing in USA

Eli Lily, the world's most valuable pharmaceutical company just announced that they will invest more than $6 billion to build a manufacturing facility in Huntsville, Alabama. This is the third new U.S. production site the company has announced as part of a $27 billion domestic manufacturing push.

The facility will produce small-molecule synthetic and peptide medicines, including orforglipron, Lilly's highly anticipated oral GLP-1 weight-loss drug expected to hit the market early next year.

The Alabama facility is believed to be massive. Construction begins in 2026 and completes in 2032, creating 3,000 construction jobs. Once operational, it will employ 450 engineers, scientists, operations personnel, and lab technicians. The company estimates every dollar invested will generate up to four dollars in local economic activity, meaning $6 billion in direct investment could translate to $24 billion in total economic impact for Alabama.

This is Lilly's ninth U.S. manufacturing site announced since 2020. In February 2025, the company committed to spending at least $27 billion on four new U.S. facilities. After hitting $1 trillion in market cap in November, the Alabama plant is the third of those four announced. A fourth location will be revealed in the coming weeks.